GNTbm's self-developed anti-cancer new drug GNTbm-38 has obtained IND approval from the U.S. FDA for Phase I clinical trials
GNTbm's self-developed anti-cancer new drug GNTbm-38 has obtained IND approval from the U.S. FDA for Phase I clinical trials is drawing significant interest across the industry.
TAIPEI, March 5, 2026 /PRNewswire/ -- Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) (stock code: 7427) announced that its independently developed novel epigenetic immunoactivator GNTbm-38, with global rights for cancer immunotherapy, has received approval from the U.S. FDA for its IND application and will proceed with patient enrollment for a Phase I clinical trial in the United States.
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- Artificial Intelligence as Financial Infrastructure: How AI Is Reshaping Modern Trading Systems
- TechEx Global returns to London with enterprise technology and AI execution
- TECNO CAMON 50 Series: Redefining Professional Imaging Through the Power of Practical AI
- How to Watch Pirates vs Phillies: Live Stream MLB Spring Training, TV Channel
Source: Original →